Retrospective Study on the Incidence and Management of Anemia in Oncology (RESPIRE)

Weprom

Status: Completed

Conditions: Anemia; Cancer

Treatments: Other: anemia assessment

Study type: Observational

Funder types: Other

Identifiers

NCT04779840

WP-2019-06

Details and patient eligibility

About

The incidence of anemia ranges from 20 to 75% depending on the type of cancer. It is often present at diagnosis and increases with specific treatments. It has an impact on overall survival and quality of life. Its origins are multiple (pure iron deficiency or functional, malnutrition, dyserythropoiesis, insufficiency renal, hemolysis, chemotherapy, radiotherapy, targeted therapies).

Transfusion is the most common treatment offered in the management of anemia. The incidence of anemia and its consequences are often underestimated during cancer management.

Recommendations were published in 2012. An inventory of the incidence of anemia before and after the publication of these recommendations are proposed in order to assess their impact on daily practice.

Enrollment: 349 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age ≥ 18 years old,
• Follow-up for cancer justifying hospitalization,
• Presenting anemia defined by a hemoglobin level <11 g / dL,
• Patient not having objected to the collection of his data after oral and written information.

Exclusion criteria

• patients with a hemoglobin level ≥ 11 g / dL,
• adult patients under guardianship, curatorship or deprived of liberty,
• pregnancy or breast-feeding in progress at the time of hospitalization.

Trial design

349 participants in 2 patient groups

period 2011

Treatment:

Other: anemia assessment

period 2018

Treatment:

Other: anemia assessment